title: The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrument.
abstract: BACKGROUND
  The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder (ADHD)-Child Version (LPS-C) was developed to capture treatment-related improvements in adaptive functioning, including quality of life, social development, and emotion regulation, that may be missed by scales that assess only the 18 ADHD symptoms in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). The 24-item LPS-C is intended to augment traditional ADHD measures. This analysis assessed the scale's psychometric properties.
  
  
  METHODS
  The LPS-C was completed by the investigators while questioning the parents of 979 children in three placebo-controlled clinical trials that measured the effects of atomoxetine for treating ADHD. In addition to a factor analysis, assessments of responsiveness; internal consistency; item-to-total correlations; and convergent, divergent, and discriminant validity were completed.
  
  
  RESULTS
  The LPS-C showed evidence of internal consistency and convergent, divergent, and discriminant validity. The factor analysis suggested two subscales (labeled the Self-Control and Agreeable subscales). The LPS-C demonstrated responsiveness in two of the three trials. The effect sizes suggest responsiveness between that for psychosocial measures and core symptom measures.
  
  
  CONCLUSIONS
  The LPS-C appears to be a valid research and clinical instrument for assessing change in ADHD-related adaptive functioning that may not be captured by traditional measures of core ADHD symptoms.
authors.affiliation: NeuroScience Inc., 106 Elden Street, Herndon, VA 20170, USA. ksaylor@neuroscience-inc.com
authors.forename: Keith
authors.initials: K
authors.lastname: Saylor
authors.forename: Curt
authors.initials: C
authors.lastname: Buermeyer
authors.forename: Virginia
authors.initials: V
authors.lastname: Sutton
authors.forename: Douglas
authors.initials: D
authors.lastname: Faries
authors.forename: Sajjad
authors.initials: S
authors.lastname: Khan
authors.forename: Kory
authors.initials: K
authors.lastname: Schuh
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002648:Child; D004644:Emotions / Q000187:drug effects; D005163:Factor Analysis, Statistical; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D010290:Parents; D011437:Propylamines / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics / Q000379:methods; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D012919:Social Behavior
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride